SALT LAKE CITY — On this video, Jay Chhablani, MD, discusses findings from the LIGHTSITE 3B research introduced on the ARVO assembly on the long-term use of photobiomodulation in dry age-related macular degeneration.
The open-label extension research included 63 eyes of 36 sufferers. The Valeda gentle supply system (LumiThera) was used each 4 months for 13 months. The photobiomodulation group confirmed higher enchancment in imaginative and prescient than the sham group, with treatment-naive instances enhancing by greater than 5 letters, in line with Chhablani, professor of ophthalmology at College of Pittsburgh College of Drugs. Over 3.7 years, eyes handled with photobiomodulation gained a median of 5.5 letters, he mentioned.
“This appears to be very thrilling, however we are going to see as extra information comes from different teams,” Chhablani mentioned.
Reference:
- Do DV, et al. LIGHTSITE IIIB: An open-label, potential, multi-center extension research to evaluate the long-term security and efficacy of photobiomodulation in dry age-related macular degeneration. Introduced at: Affiliation for Analysis in Imaginative and prescient and Ophthalmology assembly; Could 4-8, 2025; Salt Lake Metropolis.
